BioWorld

April 25, 2003

Genzyme Wins FDA Approval For Fabry's Disease Treatment

Genzyme General received FDA approval of the orphan drug Fabrazyme, an enzyme replacement therapy for a rare, genetic disorder called Fabry's disease. (BioWorld Today) Read More

High Revenues Drive Earnings Growth At Biotech Bellwethers

Coated Magnetic Beads Take Over Dendritic Cell's Flagging Down Of Invasive Antigens For Destruction

FDA Clears Path For Phase III; NeoRx Stock Soars On News

Correction

Thompson Pushes Administration Initiatives In Science Forum Talk

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 9, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...